High efficacy of two artemisinin-based combinations: Artesunate + sulfadoxine-pyrimethamine and artemether-lumefantrine for falciparum malaria in Yemen

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Adeel, Ahmed A ^a   Abdo Saeed, Niaz ^b   Aljasari, Adel ^b   Almohager, Amar M ^b   Galab, Mohamed H ^b   Almahdi, Amar ^b   Mahammed, Mansor H ^b   Aldarsi, Mohammed ^b   Salaeah, Yahiya A ^b   Atta, Hoda ^c   Zamani, Ghasem ^c   Warsame, Marian ^c   Barrette, Amy ^c   El Mohammady, Hanan ^d   Nada, Rania A ^d  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Ministry of Public Health and Population   (Yemen)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d US Naval Medical Research Unit No 3 Egypt   (Egypt)

Author keywords

Anti malarial drugs; Artemether lumefantrine; Artesunate; Drug resistance; Gametocytaemia; Plasmodium falciparum; Sulfadoxine pyrimethamine; Yemen

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; PYRIMETHAMINE PLUS SULFADOXINE; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE-ARTESUNATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLEARANCE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GAMETOCYTE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; OPEN STUDY; PARASITEMIA; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; YEMEN; CLINICAL TRIAL; DRUG COMBINATION; MALARIA, FALCIPARUM; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; ETHANOLAMINES; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMETHAMINE; SULFADOXINE; TREATMENT OUTCOME; YEMEN; YOUNG ADULT;

EID: 84951773091     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0970-2     Document Type: Article

References (35)

1. WHO. World malaria report, 2014. Geneva: World Health Organization; 2014.
2. Snow RW, Amratia P, Zamani G, Mundia CW, Noor AM, Memish ZA, et al. The malaria transition on the Arabian Peninsula: progress toward a malaria-free region between 1960-2010. Adv Parasitol. 2013;82:205-51.
3. Bamaga A, Mahdy MA, Mahmud R, Lim YA. Malaria in Hadhramout, a southeast province of Yemen: prevalence, risk factors, knowledge, attitude and practices (KAPs). Parasit Vectors. 2014;7:351.
4. WHO. Report on the inter-country workshop on monitoring therapeutic efficacy of antimalarial drugs, Annex 5: main results of monitoring drug resistance of falciparum malaria by country. Sana'a, Republic of Yemen, 21-25 April 2002, WHO-EM/MAL/281/E/L. http://whqlibdoc.who.int/emro/2002/WHO-EM-MAL-281-E-L.pdf. Accessed 11 June 2015.
5. WHO. Monitoring antimalarial drug resistance. Report of WHO Consultation, Geneva, Switzerland, 3-5 December 2001. WHO monographs WHO/CDS/CSR/EPH/2002.7.
6. Abdul-Kader R. Studies on drug resistant Plasmodium falciparum malaria in Yemen, PhD Thesis, University of Liverpool, 2006. http://library.liv.ac.uk/search∼S8?/lTHESIS+20651.MUB/lthesis+20651+mub/-3%2C-%2C0%2CE/frameset&FF=lthesis+20651+mub&1%2C1%2C. Accessed 24 Feb 2011.
7. Mubjer RA, Adeel AA, Chance ML, Hassan AA. Molecular markers of antimalarial drug resistance in Lahj Governorate, Yemen: baseline data and implications. Malar J. 2011;10:245.
8. WHO. Susceptibility of Plasmodium falciparum to antimalarial drugs: report on global monitoring: 1996-2004. WHO/HTM/MAL/2005.
9. Bloland P. Drug resistance in malaria. World Health Organization, Geneva, WHO/CDS/CSR/DRS/2001.4.
10. Al-Maktari MT, Bassiouny HK. Malaria status in Al-Hodeidah Governorate, Republic lof Yemen. Part II: human factors causing the persistence of chloroquine resistant P. falciparum local strain. J Egypt Soc Parasitol. 2003;33:829-39.
11. Bin Ghouth AS. Availability and prescription practice of anti-malaria drugs in the private health sector in Yemen. J Infect Dev Ctries. 2013;7:404-12.
12. WHO. Guidelines for the Treatment of Malaria, 3rd edn. World Health Organization: Geneva. 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/.
13. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363:9-17.
14. von Seidlein L, Milligan P, Pinder M, Bojang K, Anyalebechi C, Gosling R, et al. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet. 2000;355:352-7.
15. Omari A, Gamble C, Garner P. Artemether-lumefantrine for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev. 2007;18:CD003125.
16. WHO. Methods for Surveillance of antimalarial drug efficacy. World Health Organization: Geneva. 2009. http://www.who.int/malaria/publications/atoz/9789241597531/en/. Accessed 23 Oct 2015.
17. WHO. Methods and techniques for clinical trials on anti-malarial drug efficacy: genotyping to identify parasite populations. World Health Organization: Geneva. 2008. http://www.who.int/malaria/publications/atoz/9789241596305/en/. Accessed 23 Oct 2015.
18. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455-67.
19. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619-20.
20. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther. 2006;80:582-96.
21. Gregson A, Plowe C. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev. 2005;57:117-45.
22. Bredenkamp B, Sharp B, Mthembu SD, Durrheim DN, Barnes KI. Failure of sulfadoxine-pyrimethamine in treating Plasmodium falciparum malaria in KwaZulu-Natal. S Afr Med J. 2001;91:970-1.
23. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half- life. Trans R Soc Trop Med Hyg. 1993;87:75-8.
24. White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond Biol Sci. 1999;354:739-49.
25. Abdo-Rabbo A, Bassili A, Atta H. The quality of antimalarials available in Yemen. Malar J. 2005;4:28.
26. Abdul-Ghani R, Farag HF, Allam AF, Shawky SM, Al-Mekhlafi AM. Mutant Plasmodium falciparum chloroquine resistance transporter in Hodeidah, Yemen : association with parasitologic indices and treatment-seeking behaviors. Acta Trop. 2013;128:473-8.
27. Al-Kabsi AM, Al-Shamahy HA, Al-Harazy AH, Harmal NS. The therapeutic efficacy of sulfadoxine/pyrimethamine against Plasmodium falciparum in Yemen. Med Princ Pract. 2009;18:62-6.
28. Al-Hamidhi S, Mahdy MA, Al-Hashami Z, Al-Farsi H, Al-Mekhlafi AM, Idris MA, et al. Genetic diversity of Plasmodium falciparum and distribution of drug resistance haplotypes in Yemen. Malar J. 2013;12:244.
29. Abdul-Ghani R, Farag HF, Allam AF, Shawky SM. Prevailing Plasmodium falciparum dihydrofolate reductase 108-asparagine in Hodeidah, Yemen: a questionable sulfadoxine-pyrimethamine partner within the artemisinin-based combination therapy. Acta Trop. 2014;132:39-44.
30. Lozovsky ER, Chookajorn T, Brown KM, Imwong M, Shaw PJ, Kamchonwongpaisan S, et al. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci USA. 2009;106:12025-30.
31. Gadalla NB, Abdallah TM, Atwal S, Sutherland CJ, Adam I. Selection of pfdhfr/pfdhps alleles and declining artesunate/sulphadoxine-pyrimethamine efficacy against Plasmodium falciparum 8 years after deployment in eastern Sudan. Malar J. 2013;12:255.
32. Mula P, Fernández-Martínez A, de Lucio A, Ramos JM, Reyes F, González V, et al. Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia. Malar J. 2011;10:214.
33. Warsame M, Hassan AM, Barrette A, Jibril AM, Elmi HH, Arale AM, et al. Treatment of uncomplicated malaria with artesunate plus sulfadoxine-pyrimethamine is failing in Somalia: evidence from therapeutic efficacy studies and Pfdhfr and Pfdhps mutant alleles. Trop Med Int Health. 2015;20:510-7.
34. Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, et al. Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg. 2011;85:793-804.
35. Makanga MA. Review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmission. Malar J. 2014;13:291.